<div><p>Background</p><p>The use of temozolomide (TMZ) has improved the prognosis for glioblastoma multiforme patients. However, TMZ resistance may be one of the main reasons why treatment fails. Although this resistance has frequently been linked to the expression of O6-methylguanine-DNA methyltransferase (MGMT) it seems that this enzyme is not the only molecular mechanism that may account for the appearance of drug resistance in glioblastoma multiforme patients as the mismatch repair (MMR) complex, P-glycoprotein, and/or the presence of cancer stem cells may also be implicated.</p><p>Methods</p><p>Four nervous system tumor cell lines were used to analyze the modulation of MGMT expression and MGMT promoter methylation by TMZ treatment. Fur...
Thesis: Ph. D., Massachusetts Institute of Technology, Department of Biology, 2014.Cataloged from PD...
Glioblastoma multiforme (GBM) is the most common type of primary and malignant tumor occurring in th...
BackgroundTemozolomide (TMZ) is an oral DNA-alkylating agent used for treating patients with gliobla...
Background: The use of temozolomide (TMZ) has improved the prognosis for glioblastoma multiforme pat...
The use of temozolomide (TMZ) has improved the prognosis for glioblastoma multiforme patients. Howev...
To evaluate the mechanism of the development of therapeutic resistance after temozolomide treatment,...
Temozolomide (TMZ) was used for the treatment of glioblastoma (GBM) for over a decade, but its treat...
This is an open-access article distributed under the terms of the Creative Commons Attribution Licen...
Background:The DNA repair protein O 6-methylguanine-DNA methyltransferase (MGMT) can cause resistanc...
To evaluate the mechanism of the development of therapeutic resistance after temozolomide treatment,...
Glioblastoma leads to a fatal course within two years in more than two thirds of patients. An essent...
O -methylguanine DNA methyltransferase (MGMT) promoter methylation is a predictive biomarker for ben...
Purpose and Experimental Design: The contributions of O6-methylguanine-DNA-methyltransferase (MGMT),...
The DNA repair enzyme O6-methylguanine methyltransferase (MGMT) is a major determinant of glioma res...
Glioblastomas (GBL) are most aggressive brain tumors in adults. They are often radio- and chemothera...
Thesis: Ph. D., Massachusetts Institute of Technology, Department of Biology, 2014.Cataloged from PD...
Glioblastoma multiforme (GBM) is the most common type of primary and malignant tumor occurring in th...
BackgroundTemozolomide (TMZ) is an oral DNA-alkylating agent used for treating patients with gliobla...
Background: The use of temozolomide (TMZ) has improved the prognosis for glioblastoma multiforme pat...
The use of temozolomide (TMZ) has improved the prognosis for glioblastoma multiforme patients. Howev...
To evaluate the mechanism of the development of therapeutic resistance after temozolomide treatment,...
Temozolomide (TMZ) was used for the treatment of glioblastoma (GBM) for over a decade, but its treat...
This is an open-access article distributed under the terms of the Creative Commons Attribution Licen...
Background:The DNA repair protein O 6-methylguanine-DNA methyltransferase (MGMT) can cause resistanc...
To evaluate the mechanism of the development of therapeutic resistance after temozolomide treatment,...
Glioblastoma leads to a fatal course within two years in more than two thirds of patients. An essent...
O -methylguanine DNA methyltransferase (MGMT) promoter methylation is a predictive biomarker for ben...
Purpose and Experimental Design: The contributions of O6-methylguanine-DNA-methyltransferase (MGMT),...
The DNA repair enzyme O6-methylguanine methyltransferase (MGMT) is a major determinant of glioma res...
Glioblastomas (GBL) are most aggressive brain tumors in adults. They are often radio- and chemothera...
Thesis: Ph. D., Massachusetts Institute of Technology, Department of Biology, 2014.Cataloged from PD...
Glioblastoma multiforme (GBM) is the most common type of primary and malignant tumor occurring in th...
BackgroundTemozolomide (TMZ) is an oral DNA-alkylating agent used for treating patients with gliobla...